Short-course radiation with chemotherapy and immunotherapy for rectal cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of brief radiation therapy, two chemotherapy drugs (nal-IRI and capecitabine), and an immunotherapy drug (camrelizumab) for locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes before surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–75 years old
- Diagnosed with rectal adenocarcinoma (a type of rectal cancer) confirmed by biopsy
- Cancer is microsatellite stable (MSS) or mismatch repair proficient (pMMR)—a genetic test result
- Cancer is locally advanced (spread to nearby lymph nodes or into the rectal wall, but not to distant organs)
- Tumor is in the lower or middle part of the rectum (within 10 cm of the anus)
- Good overall health and organ function (blood counts, liver, and kidney tests within acceptable limits)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares a new treatment approach—short-course radiation followed by an immunotherapy drug (PD-1 inhibitor) and chemotherapy (FOLFOX)—to the standard long-course chemoradiation for people with a specific type of advanced rectal cancer that is pMMR/MSS. The goal is to see if the shorter treatment works as well or better.
This trial tests a treatment plan that uses a short course of radiation to the lymph nodes-sparing area, followed by chemotherapy and an immunotherapy drug (PD-1 inhibitor) for people with a specific type of mid or low rectal cancer (pMMR/MSS). The goal is to see if this approach can shrink the tumor and improve outcomes without needing extensive surgery.
This trial tests a treatment plan involving radiation, chemotherapy, and an immunotherapy drug (a PD-1 inhibitor) for people with a specific type of high-risk rectal cancer. The goal is to see if this combination helps shrink the tumor before surgery.
This trial tests a combination of short course radiation therapy, chemotherapy, and two immunotherapy drugs for people with a specific type of rectal cancer that is locally advanced but can still be removed by surgery. It may offer a more effective treatment option for those with mismatch repair proficient (pMMR) or microsatellite stable (MSS) tumors.
This trial tests a short course of radiation therapy combined with chemotherapy and immunotherapy for people with mid-to-low rectal cancer that hasn't spread. It aims to see if this combination can shrink the tumor and improve outcomes.
This trial tests a combination of short-course radiation, two chemotherapy drugs (liposomal irinotecan and capecitabine), and an immunotherapy drug (Enlonstobart) for people with locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor before surgery.
Hear when a new Rectal Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.